- SmartCella has entered a nonexclusive licence agreement with Catalent to use proprietary GMP-compliant iPSCs for research, development and clinical translation.
- The agreement supports regenerative medicine programmes targeting cardiac disease and Parkinson’s disease.
SmartCella Holding AB has signed a nonexclusive licence agreement with Catalent to access Catalent’s proprietary off-the-shelf, GMP-compliant induced pluripotent stem cells (iPSCs). The agreement covers use of the iPSCs for research, development and clinical translation of allogeneic stem cell-based regenerative therapies.
The partnership focuses on supporting regenerative medicine programmes targeting cardiac disease and Parkinson’s disease. Under the terms of the agreement, SmartCella will use Catalent’s iPSC platform as a foundation for developing novel cell-based therapies as they progress towards clinical application.
Catalent stated that the agreement builds on its role as a CDMO with capabilities in developing iPSCs and iPSC-derived cell therapies. The company will provide access to its GMP-compliant iPSC technology to support SmartCella’s development activities within a regulated manufacturing framework, aligning with contract manufacturing requirements for advanced therapies.
“As a global CDMO with leading capabilities developing iPSCs and iPSC-derived cell therapies, Catalent is pleased to partner with SmartCella, a leading biopharma advancing innovative cell-based therapeutics.”
David McErlane, Biologics Group President at Catalent
SmartCella said access to well-characterised iPSC lines supports scalable manufacturing and helps de-risk future scale-up and GMP implementation. The company added that the collaboration underpins its regenerative medicine platforms, with current development efforts focused on Parkinson’s disease, cardiac failure and osteoarthritis.
